Japan Society of Gynecologic Oncology 2023 guidelines for treatment of uterine body neoplasm
The Japan Society of Gynecologic Oncology (JSGO) guideline for the treatment of uterine body neoplasm are revised from the 2018 guideline. This guideline aimed to provide standardized care for uterine body neoplasm, indicate appropriate current treatment methods for uterine body neoplasm, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the economic and psychosomatic burden on patients by promoting the performance of appropriate treatment, and enhance mutual understanding between patients and healthcare professionals. The guidelines were prepared through the consensus of the JSGO guideline committee, based on a careful review of evidence from the literature searches and the medical health insurance system and actual clinical practice situations in Japan. The main features of the 2023 revision are as follows: 1) The Guidelines Formulation Committee members were asked to understand Minds' medical guideline development method in advance. 2) The clinical question (CQ) was changed to Patient, Intervention, Comparison, Outcome format as much as possible. 3) Introduced the "body of evidence," which summarizes the results of research reports collected for the CQs by outcome and study design, and the strength of evidence for each body of evidence was rated from levels A to D. 4) Introduction of systematic reviews in some CQs. 5) The strength of evidence, the balance of benefits and harms, value and hope for patients, and clinical applicability were considered while drafting recommendations. Herein, we present the English version of the JSGO guidelines 2023 for the treatment of uterine body neoplasm.
Authors
- Kenichi Harano (ORCID: https://orcid.org/0000-0002-0833-3489)
- Yasuyuki Hirashima (ORCID: https://orcid.org/0000-0003-0269-9313)
- Yoshito Terai (ORCID: https://orcid.org/0000-0002-5581-8518)
- Tohru Morisada (ORCID: https://orcid.org/0000-0002-4223-1291)
- Yasuhisa Terao (ORCID: https://orcid.org/0000-0002-9126-3361)
- Tsukasa Baba (ORCID: https://orcid.org/0000-0003-0066-3747)
- Tsutomu Tabata (ORCID: https://orcid.org/0000-0003-0243-8180)
- Hidemichi Watari (ORCID: https://orcid.org/0000-0002-4189-6187)
- Kazuhiro Takehara (ORCID: https://orcid.org/0000-0001-8808-3338)
- Hideki Tokunaga (ORCID: https://orcid.org/0000-0002-1622-3810)
- Satoru Nagase (ORCID: https://orcid.org/0000-0001-5212-1128)
- Aikou Okamoto (ORCID: https://orcid.org/0000-0002-5079-0464)
- Munetaka Takekuma (ORCID: https://orcid.org/0000-0002-0807-1845)
- Yoichi Kobayashi (ORCID: https://orcid.org/0000-0002-8474-0625)
- Mikiko Asai‐Sato (ORCID: https://orcid.org/0000-0002-7811-947X)
- Hiroaki Kajiyama (ORCID: https://orcid.org/0000-0003-0493-1825)
- Mayu Yunokawa (ORCID: https://orcid.org/0000-0001-7354-6977)
- Mikio Mikami (ORCID: https://orcid.org/0000-0002-7496-3518)
Institutions
- Yamagata University (JP)
- Jikei University School of Medicine (JP)
- Iwate Medical University (JP)
- Kyorin University (JP)
- Hokkaido University (JP)
- Juntendo University (JP)
- St. Luke's International Hospital (JP)
- Shizuoka Cancer Center (JP)
- Chigasaki Rehabilitation College (JP)
- Tokyo Women's Medical University (JP)
- Shonan University of Medical Sciences (JP)
- Shikoku Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Japanese Foundation For Cancer Research (JP)
- Nagoya University (JP)
- Kobe University (JP)
- Tohoku Medical and Pharmaceutical University (JP)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.3802/jgo.2025.36.e119
- Citations
- 6
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.34